Back to School: How biopharma can reboot drug development. Access exclusive analysis here

New Dyrction

Xoma spinout Symplmed to use new platform to market blood pressure meds

Symplmed Pharmaceuticals LLC found an individual investor who has bought into the company's plan of introducing a disruptive sales strategy that incentivizes doctors and patients to use its blood pressure therapies.

The newco, which spun out of Xoma Corp. (NASDAQ:XOMA) this month, will start rolling out its Dyrct Axess marketing platform this quarter using Aceon perindopril as its

Read the full 573 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE